Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer
This study evaluated the efficacy and safety of pemetrexed, carboplatin, and bevacizumab followed by maintenance pemetrexed and bevacizumab in patients with chemotherapy-naive stage IIIB (effusion) or stage IV nonsquamous non-small-cell lung cancer (NSCLC). Patients received pemetrexed 500 mg/m(2),...
Saved in:
Published in | Journal of clinical oncology Vol. 27; no. 20; pp. 3284 - 3289 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Alexandria, VA
American Society of Clinical Oncology
10.07.2009
|
Subjects | |
Online Access | Get full text |
ISSN | 0732-183X 1527-7755 |
DOI | 10.1200/JCO.2008.20.8181 |
Cover
Abstract | This study evaluated the efficacy and safety of pemetrexed, carboplatin, and bevacizumab followed by maintenance pemetrexed and bevacizumab in patients with chemotherapy-naive stage IIIB (effusion) or stage IV nonsquamous non-small-cell lung cancer (NSCLC).
Patients received pemetrexed 500 mg/m(2), carboplatin area under the concentration-time curve of 6, and bevacizumab 15 mg/kg every 3 weeks for six cycles. For patients with response or stable disease, pemetrexed and bevacizumab were continued until disease progression or unacceptable toxicity.
Fifty patients were enrolled and received treatment. The median follow-up was 13.0 months, and the median number of treatment cycles was seven (range, one to 51). Thirty patients (60%) completed > or = six treatment cycles, and nine (18%) completed > or = 18 treatment cycles. Among the 49 patients assessable for response, the objective response rate was 55% (95% CI, 41% to 69%). Median progression-free and overall survival rates were 7.8 months (95% CI, 5.2 to 11.5 months) and 14.1 months (95% CI, 10.8 to 19.6 months), respectively. Grade 3/4 hematologic toxicity was modest-anemia (6%; 0), neutropenia (4%; 0), and thrombocytopenia (0; 8%). Grade 3/4 nonhematologic toxicities were proteinuria (2%; 0), venous thrombosis (4%; 2%), arterial thrombosis (2%; 0), fatigue (8%; 0), infection (8%; 2%), nephrotoxicity (2%; 0), and diverticulitis (6%; 2%). There were no grade 3 or greater hemorrhagic events or hypertension cases.
This regimen, involving a maintenance component, was associated with acceptable toxicity and relatively long survival in patients with advanced nonsquamous NSCLC. These results justify a phase III comparison against the standard-of-care in this patient population. |
---|---|
AbstractList | This study evaluated the efficacy and safety of pemetrexed, carboplatin, and bevacizumab followed by maintenance pemetrexed and bevacizumab in patients with chemotherapy-naive stage IIIB (effusion) or stage IV nonsquamous non-small-cell lung cancer (NSCLC).
Patients received pemetrexed 500 mg/m(2), carboplatin area under the concentration-time curve of 6, and bevacizumab 15 mg/kg every 3 weeks for six cycles. For patients with response or stable disease, pemetrexed and bevacizumab were continued until disease progression or unacceptable toxicity.
Fifty patients were enrolled and received treatment. The median follow-up was 13.0 months, and the median number of treatment cycles was seven (range, one to 51). Thirty patients (60%) completed > or = six treatment cycles, and nine (18%) completed > or = 18 treatment cycles. Among the 49 patients assessable for response, the objective response rate was 55% (95% CI, 41% to 69%). Median progression-free and overall survival rates were 7.8 months (95% CI, 5.2 to 11.5 months) and 14.1 months (95% CI, 10.8 to 19.6 months), respectively. Grade 3/4 hematologic toxicity was modest-anemia (6%; 0), neutropenia (4%; 0), and thrombocytopenia (0; 8%). Grade 3/4 nonhematologic toxicities were proteinuria (2%; 0), venous thrombosis (4%; 2%), arterial thrombosis (2%; 0), fatigue (8%; 0), infection (8%; 2%), nephrotoxicity (2%; 0), and diverticulitis (6%; 2%). There were no grade 3 or greater hemorrhagic events or hypertension cases.
This regimen, involving a maintenance component, was associated with acceptable toxicity and relatively long survival in patients with advanced nonsquamous NSCLC. These results justify a phase III comparison against the standard-of-care in this patient population. |
Author | Jyoti D. Patel Alfred Rademaker Daniel T. Milton Thomas A. Hensing Matthew G. Blum Philip D. Bonomi Eric M. Hart |
Author_xml | – sequence: 1 givenname: Jyoti D. surname: Patel fullname: Patel, Jyoti D. organization: From the Feinberg School of Medicine, Northwestern University, The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Eli Lilly Pharmaceuticals; Hematology/Oncology of Indiana, Indianapolis, IN; and the Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL – sequence: 2 givenname: Thomas A. surname: Hensing fullname: Hensing, Thomas A. organization: From the Feinberg School of Medicine, Northwestern University, The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Eli Lilly Pharmaceuticals; Hematology/Oncology of Indiana, Indianapolis, IN; and the Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL – sequence: 3 givenname: Alfred surname: Rademaker fullname: Rademaker, Alfred organization: From the Feinberg School of Medicine, Northwestern University, The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Eli Lilly Pharmaceuticals; Hematology/Oncology of Indiana, Indianapolis, IN; and the Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL – sequence: 4 givenname: Eric M. surname: Hart fullname: Hart, Eric M. organization: From the Feinberg School of Medicine, Northwestern University, The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Eli Lilly Pharmaceuticals; Hematology/Oncology of Indiana, Indianapolis, IN; and the Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL – sequence: 5 givenname: Matthew G. surname: Blum fullname: Blum, Matthew G. organization: From the Feinberg School of Medicine, Northwestern University, The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Eli Lilly Pharmaceuticals; Hematology/Oncology of Indiana, Indianapolis, IN; and the Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL – sequence: 6 givenname: Daniel T. surname: Milton fullname: Milton, Daniel T. organization: From the Feinberg School of Medicine, Northwestern University, The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Eli Lilly Pharmaceuticals; Hematology/Oncology of Indiana, Indianapolis, IN; and the Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL – sequence: 7 givenname: Philip D. surname: Bonomi fullname: Bonomi, Philip D. organization: From the Feinberg School of Medicine, Northwestern University, The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Eli Lilly Pharmaceuticals; Hematology/Oncology of Indiana, Indianapolis, IN; and the Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21741912$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19433684$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kcFu1DAQhi1URLeFOyfkC-KUxU6cjX0sES2LFrpSi-BmTZxJ11XibO0Eupx4B16Dp-JJcLSlQpW4zPjw_eN_5j8iB653SMhzzuY8Zez1-_J8HruMZS655I_IjOdpkRRFnh-QGSuyNOEy-3JIjkK4ZowLmeVPyCFXIssWUszIr_UGAtLlkl4MY72jfUPX2OHg8RZrCq6mJfiq37YwWEfX7RjoG_wKxn4fO6joZzts6AewbkAHzuBD8b_sSaCn1ochWVmH9HKDHrY72vSefuxduBmh6-P0-P794-dFB22blNi2dDW6q2giDvdPyeMG2oDP7vox-XT69rJ8l6zOz5blySoxgvEhKWqDSixUzfNKKVXVEg2IXAIAE1wxzKWQoDgrCpk2sjY5NJmpFAglhKyy7Ji82M_djlWHtd5624Hf6b9ni8DLOwCCgbbx0Z4N91zKi_gPTyO32HPG9yF4bLSxQ7xk7wYPttWc6SlHHXPUU46x6CnHKGQPhPce_i95tZds7NXmm_Wow3TEuEKqr02fFhOZpdH9H1mRrz8 |
CitedBy_id | crossref_primary_10_1200_JOP_2011_000502 crossref_primary_10_1016_S1877_1203_12_70311_7 crossref_primary_10_1200_JCO_19_00201 crossref_primary_10_2146_ajhp090455 crossref_primary_10_1097_JTO_0b013e3181ee820c crossref_primary_10_1016_j_cllc_2011_08_006 crossref_primary_10_1016_j_lungcan_2013_07_008 crossref_primary_10_1200_JCO_19_02741 crossref_primary_10_1053_j_seminoncol_2013_12_007 crossref_primary_10_3389_fonc_2022_967675 crossref_primary_10_1002_cncr_29800 crossref_primary_10_1016_j_lungcan_2014_07_003 crossref_primary_10_1517_14656566_2012_668530 crossref_primary_10_1517_14656566_2012_693165 crossref_primary_10_1016_j_ejca_2016_01_013 crossref_primary_10_1038_bjc_2013_368 crossref_primary_10_1684_bdc_2012_1655 crossref_primary_10_1016_j_actbio_2018_01_015 crossref_primary_10_1002_cncr_24996 crossref_primary_10_1164_rccm_201702_0433CI crossref_primary_10_1016_j_lungcan_2011_05_004 crossref_primary_10_1586_era_12_171 crossref_primary_10_1200_JCO_19_02356 crossref_primary_10_1007_s40265_013_0032_4 crossref_primary_10_1002_cncr_27576 crossref_primary_10_1080_14740338_2017_1372421 crossref_primary_10_3390_ijms22094618 crossref_primary_10_1007_s10147_014_0755_6 crossref_primary_10_2217_fon_13_247 crossref_primary_10_1007_s00280_013_2100_6 crossref_primary_10_3760_cma_j_issn_0366_6999_20123564 crossref_primary_10_1038_bjc_2013_735 crossref_primary_10_1586_14737140_2013_845093 crossref_primary_10_3816_CLC_2010_n_045 crossref_primary_10_4137_CMO_S6248 crossref_primary_10_1177_2042098611430109 crossref_primary_10_18632_oncotarget_13922 crossref_primary_10_3892_ol_2014_2552 crossref_primary_10_4046_trd_2014_76_1_1 crossref_primary_10_1007_s00280_012_2037_1 crossref_primary_10_1016_j_cllc_2015_12_006 crossref_primary_10_1200_JCO_2012_47_9626 crossref_primary_10_1097_JTO_0b013e3181f1d23c crossref_primary_10_1177_1758834013510589 crossref_primary_10_1517_14728222_2012_669752 crossref_primary_10_3111_13696998_2014_912987 crossref_primary_10_1200_JCO_19_01006 crossref_primary_10_1016_j_jtho_2016_02_018 crossref_primary_10_1053_j_seminoncol_2012_11_004 crossref_primary_10_2217_lmt_12_32 crossref_primary_10_1007_s11864_013_0255_3 crossref_primary_10_1097_CAD_0b013e328334da02 crossref_primary_10_18632_oncotarget_17957 crossref_primary_10_1007_s00280_013_2301_z crossref_primary_10_1111_jcpt_13534 crossref_primary_10_1016_j_pneumo_2013_02_006 crossref_primary_10_1586_era_12_13 crossref_primary_10_1093_annonc_mdu098 crossref_primary_10_3109_07357907_2011_554476 crossref_primary_10_3892_ol_2016_5268 crossref_primary_10_1097_CCO_0b013e32833681df crossref_primary_10_1586_erp_12_42 crossref_primary_10_3816_CLC_2010_n_025 crossref_primary_10_1097_JTO_0b013e3181d3504d crossref_primary_10_18553_jmcp_2017_23_2_195 crossref_primary_10_2165_11590180_000000000_00000 crossref_primary_10_1053_j_ajkd_2016_04_016 crossref_primary_10_1016_j_cllc_2012_10_010 crossref_primary_10_2217_lmt_14_25 crossref_primary_10_1517_13543784_2013_775243 crossref_primary_10_1016_j_lungcan_2012_06_008 crossref_primary_10_1016_j_rmr_2011_06_017 crossref_primary_10_1200_JCO_2015_62_1342 crossref_primary_10_1097_JTO_0b013e3182307efe crossref_primary_10_1016_j_lungcan_2010_08_018 crossref_primary_10_1186_s40792_019_0722_6 crossref_primary_10_1634_theoncologist_2014_0212 crossref_primary_10_1185_03007995_2011_626019 crossref_primary_10_1634_theoncologist_2010_0322 crossref_primary_10_1200_JCO_2012_42_3749 crossref_primary_10_1016_S1877_1203_10_70078_1 crossref_primary_10_1097_JTO_0b013e3181fd42eb crossref_primary_10_1097_JTO_0b013e3181cee24f crossref_primary_10_1016_j_hoc_2012_02_013 crossref_primary_10_1016_j_jval_2022_11_018 crossref_primary_10_1093_icvts_ivr036 crossref_primary_10_1200_JCO_2012_43_1858 crossref_primary_10_1517_14656566_2010_482560 crossref_primary_10_1634_theoncologist_2009_0306 crossref_primary_10_1097_CCO_0b013e32833edc0c crossref_primary_10_1016_j_lungcan_2010_02_007 crossref_primary_10_1097_MD_0000000000003351 crossref_primary_10_1097_JTO_0000000000000217 crossref_primary_10_4236_jct_2011_23042 crossref_primary_10_1155_2018_5839081 crossref_primary_10_1586_era_09_141 crossref_primary_10_4161_cbt_19594 crossref_primary_10_1016_S1877_1203_12_70312_9 crossref_primary_10_3816_CLC_2009_n_035 crossref_primary_10_1016_j_cllc_2017_10_007 crossref_primary_10_1097_JTO_0000000000000572 crossref_primary_10_1007_s10637_012_9900_0 crossref_primary_10_1007_s00408_018_0110_1 crossref_primary_10_1097_CCO_0b013e328335a583 crossref_primary_10_1586_era_11_146 crossref_primary_10_1016_S1548_5315_12_70045_1 crossref_primary_10_1016_S1470_2045_16_30532_0 crossref_primary_10_1177_1758834016644155 crossref_primary_10_1002_cac2_12294 crossref_primary_10_4137_CMT_S5262 crossref_primary_10_1016_j_lungcan_2012_01_014 crossref_primary_10_1158_1078_0432_CCR_09_2328 crossref_primary_10_1007_s13277_014_2862_4 crossref_primary_10_1016_j_rmr_2013_05_011 crossref_primary_10_1016_j_rmr_2011_04_014 crossref_primary_10_1586_era_11_80 crossref_primary_10_1007_s10147_019_01548_1 crossref_primary_10_1016_j_critrevonc_2011_08_003 crossref_primary_10_1517_14656566_2013_802774 crossref_primary_10_1142_S0192415X13500523 crossref_primary_10_1146_annurev_med_041316_085813 crossref_primary_10_2165_11636760_000000000_00000 crossref_primary_10_1053_j_seminoncol_2013_12_013 |
Cites_doi | 10.1200/JCO.2003.11.136 10.1097/01.JTO.0000283379.01457.db 10.1093/annonc/mdj054 10.1200/jco.2008.26.15_suppl.8011 10.1038/sj.bjc.6603383 10.2307/2530286 10.1053/sonc.2002.37476 10.1200/JCO.2007.15.0375 10.1038/nature04483 10.1200/JCO.2004.08.163 10.1054/bjoc.1999.1129 10.1016/j.lungcan.2005.09.005 10.1200/jco.2008.26.15_suppl.8080 10.1200/jco.2007.25.18_suppl.7517 10.1093/annonc/mdn540 10.1136/bmj.311.7010.899 10.1634/theoncologist.2008-0016 10.1097/JTO.0b013e318187490c 10.1038/nm988 10.1016/S1556-0864(15)33313-X 10.1200/JCO.2001.19.6.1734 10.1200/jco.2002.20.5.1335 10.1038/nm0901-987 10.1056/NEJMoa011954 10.1093/annonc/mdl396 10.1056/NEJMoa061884 10.1200/JCO.2007.12.3026 10.1200/JCO.2008.17.7162 10.1200/jco.2007.25.18_suppl.lba7516 10.1200/JCO.2001.19.5.1336 10.1097/JTO.0b013e3181461976 10.1093/annonc/mdm374 10.1016/j.lungcan.2006.01.006 10.1038/362841a0 10.1200/jco.2007.25.18_suppl.lba7514 |
ContentType | Journal Article |
Copyright | 2009 INIST-CNRS |
Copyright_xml | – notice: 2009 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM |
DOI | 10.1200/JCO.2008.20.8181 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 3289 |
ExternalDocumentID | 19433684 21741912 10_1200_JCO_2008_20_8181 jco27_20_3284 |
Genre | Multicenter Study Clinical Trial, Phase II Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - 0R 2WC 34G 39C 3O- 4.4 53G 55 5GY 5RE 8F7 8WZ A6W AAPEM AARDX AAWTL AAYEP ABFLS ABOCM ACDCL ACGFS ADBBV ADKWQ AENEX AFFNX ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL CS3 DIK EBS EJD F5P FD8 FH7 GX1 H13 HZ IH2 K-O KQ8 L7B LSO N9A O9- OK1 OVD OWW P2P RHI RUC SJN SV3 TWZ UDS VH1 WH7 X7M YCJ ZA5 --- .55 0R~ 18M AAYOK AAYXX ABBLC ABJNI ACGFO ACGUR AEGXH AI. AIAGR C45 CITATION F9R FBNNL HZ~ MJL N4W QTD R1G RLZ TEORI TR2 VVN YFH YQY .GJ 08G 08P 29K 5VS AAKAS AAQOH AAQQT ADZCM ASPBG AVWKF AZFZN BYPQX D-I EX3 FEDTE HVGLF IPNFZ IQODW J5H NTWIH RIG UHU WOQ WOW ZGI CGR CUY CVF ECM EIF NPM |
ID | FETCH-LOGICAL-c401t-7dce9469d15b999bd8eca458aaa04190e5848a9107782f8dc5af3cb9a49448b33 |
ISSN | 0732-183X |
IngestDate | Mon Jul 21 05:38:27 EDT 2025 Mon Jul 21 09:13:59 EDT 2025 Tue Jul 01 01:11:14 EDT 2025 Thu Apr 24 23:03:00 EDT 2025 Tue Jan 05 20:16:52 EST 2021 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 20 |
Keywords | Antineoplastic agent Lung disease Respiratory disease Lung cancer Monoclonal antibody Malignant tumor non-small cell lung carcinoma Pemetrexed Bevacizumab First line treatment Antifolate Cancerology Vascular endothelium growth factor Phase II trial Carboplatin Bronchus disease Antiangiogenic agent Cancer Platinum II Complexes |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c401t-7dce9469d15b999bd8eca458aaa04190e5848a9107782f8dc5af3cb9a49448b33 |
OpenAccessLink | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2008.20.8181?role=tab |
PMID | 19433684 |
PageCount | 6 |
ParticipantIDs | pubmed_primary_19433684 pascalfrancis_primary_21741912 crossref_citationtrail_10_1200_JCO_2008_20_8181 crossref_primary_10_1200_JCO_2008_20_8181 highwire_smallpub2_jco27_20_3284 |
ProviderPackageCode | RHI CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2009-07-10 |
PublicationDateYYYYMMDD | 2009-07-10 |
PublicationDate_xml | – month: 07 year: 2009 text: 2009-07-10 day: 10 |
PublicationDecade | 2000 |
PublicationPlace | Alexandria, VA |
PublicationPlace_xml | – name: Alexandria, VA – name: United States |
PublicationTitle | Journal of clinical oncology |
PublicationTitleAlternate | J Clin Oncol |
PublicationYear | 2009 |
Publisher | American Society of Clinical Oncology |
Publisher_xml | – name: American Society of Clinical Oncology |
References | B20 B21 B22 B23 Manegold C (B18) 2007; 25 B24 B25 B26 B28 B29 Reck M (B19) 2008; 3 Comella P (B35) 2007; 18 B30 B31 B32 B11 B33 B12 B34 B13 B14 B36 B15 B16 Grønberg B (B10) 2007; 25 B17 B1 B2 B3 B4 Shih C (B8) 1997; 57 B5 B6 B7 B9 Fidias P (B27) 2007; 25 |
References_xml | – ident: B5 doi: 10.1200/JCO.2003.11.136 – ident: B24 doi: 10.1097/01.JTO.0000283379.01457.db – ident: B7 doi: 10.1093/annonc/mdj054 – ident: B25 doi: 10.1200/jco.2008.26.15_suppl.8011 – ident: B23 doi: 10.1038/sj.bjc.6603383 – ident: B20 doi: 10.2307/2530286 – ident: B6 doi: 10.1053/sonc.2002.37476 – ident: B11 doi: 10.1200/JCO.2007.15.0375 – ident: B12 doi: 10.1038/nature04483 – ident: B9 doi: 10.1200/JCO.2004.08.163 – volume: 57 start-page: 1116 year: 1997 ident: B8 publication-title: Cancer Res – ident: B13 doi: 10.1054/bjoc.1999.1129 – ident: B14 doi: 10.1016/j.lungcan.2005.09.005 – ident: B29 doi: 10.1200/jco.2008.26.15_suppl.8080 – volume: 25 start-page: 388s year: 2007 ident: B10 publication-title: J Clin Oncol doi: 10.1200/jco.2007.25.18_suppl.7517 – ident: B30 doi: 10.1093/annonc/mdn540 – ident: B1 doi: 10.1136/bmj.311.7010.899 – ident: B31 doi: 10.1634/theoncologist.2008-0016 – ident: B36 doi: 10.1097/JTO.0b013e318187490c – ident: B16 doi: 10.1038/nm988 – volume: 3 start-page: S302 year: 2008 ident: B19 publication-title: J Thorac Oncol doi: 10.1016/S1556-0864(15)33313-X – ident: B3 doi: 10.1200/JCO.2001.19.6.1734 – ident: B22 doi: 10.1200/jco.2002.20.5.1335 – ident: B32 doi: 10.1038/nm0901-987 – ident: B4 doi: 10.1056/NEJMoa011954 – volume: 18 start-page: 324 year: 2007 ident: B35 publication-title: Ann Oncol doi: 10.1093/annonc/mdl396 – ident: B17 doi: 10.1056/NEJMoa061884 – ident: B28 doi: 10.1200/JCO.2007.12.3026 – ident: B2 doi: 10.1200/JCO.2008.17.7162 – volume: 25 start-page: 388s year: 2007 ident: B27 publication-title: J Clin Oncol doi: 10.1200/jco.2007.25.18_suppl.lba7516 – ident: B21 doi: 10.1200/JCO.2001.19.5.1336 – ident: B33 doi: 10.1097/JTO.0b013e3181461976 – ident: B34 doi: 10.1093/annonc/mdm374 – ident: B26 doi: 10.1016/j.lungcan.2006.01.006 – ident: B15 doi: 10.1038/362841a0 – volume: 25 start-page: 388s year: 2007 ident: B18 publication-title: J Clin Oncol doi: 10.1200/jco.2007.25.18_suppl.lba7514 |
SSID | ssj0014835 |
Score | 2.3858478 |
Snippet | This study evaluated the efficacy and safety of pemetrexed, carboplatin, and bevacizumab followed by maintenance pemetrexed and bevacizumab in patients with... |
SourceID | pubmed pascalfrancis crossref highwire |
SourceType | Index Database Enrichment Source Publisher |
StartPage | 3284 |
SubjectTerms | Adult Aged Aged, 80 and over Anemia - chemically induced Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Biological and medical sciences Carboplatin - administration & dosage Carboplatin - adverse effects Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Disease-Free Survival Drug Administration Schedule Fatigue - chemically induced Female Follow-Up Studies Glutamates - administration & dosage Glutamates - adverse effects Guanine - administration & dosage Guanine - adverse effects Guanine - analogs & derivatives Humans Kaplan-Meier Estimate Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medical sciences Middle Aged Neoplasm Staging Neutropenia - chemically induced Pemetrexed Pneumology Thrombocytopenia - chemically induced Treatment Outcome Tumors Tumors of the respiratory system and mediastinum |
Title | Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer |
URI | http://jco.ascopubs.org/content/27/20/3284.abstract https://www.ncbi.nlm.nih.gov/pubmed/19433684 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF6FIiFeEJQrHNU-oEoodWuv19djFUAJqDRCqdS3aNdeq0E-QmIj0p_EX-DPMXs4dgJFwIsV2XsomS_jmdlvZhB6lTI_oHbMLZJScFBoLKyQeYnlJK6dxIxGjjrBP_vojy7o-0vvstf70WEt1RU_jq9_m1fyP1KFeyBXmSX7D5LdLAo34DPIF64gYbj-lYwnV_AOGozHukisIi-LXFRL8U0kOmGNLXm5kHS3YrDI6tWAi68snl_XOeM6BJszWTCiUIkDO5O7Y9lqkM7BULSUVaqTtjTVs4Av96Vmuar0WhbWKmdZZsnzgEFWy4ReufTyBht4k5dZFvFWfH8CJrAOTq_Lat7SkkeSb6_Vk6Y2tbHYT5LozwxJ5DRLmx6kSr3qxCSp9E34twl0yNwqy1BehVHOJABvQJf1bbS3rixgUErsji52iW4-98tLguj-18NzTaUl9jFYLU53KIh5kSvQOBF1XV8vtFOYu3l0C90mge_L9hlvxh82R1gUbFtzLg7bnOxup6rV6gW2TaKmTLVk6bIViCDVHVZ2_B5l_0zvo3tGaPhUo_AB6oliH905M9SMfXQ40UXQ10d42ub0rY7wIZ605dHXD9F3hVo8HmOFWlymuAUeBuDhDmqxRC3uIBFL1OIOancnd8eyFW5Riw1qMaAWd1CLt1GLJWqxRu0jdPHu7XQ4skzHECumtlNZQRKLiPpR4ngcPB-ehAL0jRcyxmwKWkeAuR0ysJADMIzTMIk9lroxj0AnURpy132M9mBT8RRheZ7t-D6LbOpSkYbcTsBVEDbMBuPC43100ghtFpty-rKrSzaTbjWRZ8TDc93kldgzKfE-er2ZsdClZP4wFjc4mKlfAERPZp_jkgRyiIR2Hx1s4WOzpgwyOJFD-uiJBky7mwHcsxufPEd327_eC7RXLWvxEqzuih8odP8EgNzdTg |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+II+study+of+pemetrexed+and+carboplatin+plus+bevacizumab+with+maintenance+pemetrexed+and+bevacizumab+as+first-line+therapy+for+nonsquamous+non-small-cell+lung+cancer&rft.jtitle=Journal+of+clinical+oncology&rft.au=Patel%2C+Jyoti+D&rft.au=Hensing%2C+Thomas+A&rft.au=Rademaker%2C+Alfred&rft.au=Hart%2C+Eric+M&rft.date=2009-07-10&rft.eissn=1527-7755&rft.volume=27&rft.issue=20&rft.spage=3284&rft_id=info:doi/10.1200%2FJCO.2008.20.8181&rft_id=info%3Apmid%2F19433684&rft.externalDocID=19433684 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |